# Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC

> **NCT00519831** · PHASE2 · TERMINATED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** vinflunine

## Key facts

- **NCT ID:** NCT00519831
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08
- **Primary completion:** 2008-02
- **Final completion:** 2009-11
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Drug unavailable
- **Last updated:** 2017-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00519831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00519831, "Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00519831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*